Goldman Sachs analysts added AstraZeneca (AZN) to the firm’s European Conviction List as part of its monthly update. With 28 Phase-3 readouts across multiple therapeutic areas expected in 2025, AstraZeneca can “de-risk” $20B in aggregate peak sales, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- Amgen, AstraZeneca announce results from Phase 3 WAYPOINT trial on tezspire
- AIM announces principal investigator for Ampligen, FluMist clinical study
- AstraZeneca Enhertu recommended for approval in EU by CHMP
- AstraZeneca, Daiichi Sankyo’s Enhertu recommended for approval in EU
- AstraZeneca data ‘positive’ for Olema’s palazestrant, says H.C. Wainwright